Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Front Immunol ; 12: 660361, 2021.
Article in English | MEDLINE | ID: mdl-34526984

ABSTRACT

Gamma delta (γδ) T cells, especially the Vγ9Vδ2 subtype, have been implicated in cancer therapy and thus have earned the spotlight in the past decade. Although one of the most important properties of γδ T cells is their activation by phosphoantigens, which are intermediates of the Mevalonate and Rohmer pathway of isoprenoid biosynthesis, such as IPP and HDMAPP, respectively, the global effects of such treatments on Vγ9Vδ2 T cells remain elusive. Here, we used the high-throughput transcriptomics approach to elucidate the transcriptional changes in human Vγ9Vδ2 T cells upon HDMAPP, IPP, and anti-CD3 treatments in combination with interleukin 2 (IL2) cytokine stimulation. These activation treatments exhibited a dramatic surge in transcription with distinctly enriched pathways. We further assessed the transcriptional dynamics upon inhibition of Notch signaling coupled with activation treatments. We observed that the metabolic processes are most affected upon Notch inhibition via GSI-X. The key effector genes involved in gamma-delta cytotoxic function were downregulated upon Notch blockade even in combination with activation treatment, suggesting a transcriptional crosstalk between T-cell receptor (TCR) signaling and Notch signaling in Vγ9Vδ2 T cells. Collectively, we demonstrate the effect of the activation of TCR signaling by phosphoantigens or anti-CD3 on the transcriptional status of Vγ9Vδ2 T cells along with IL2 stimulation. We further show that the blockade of Notch signaling antagonistically affects this activation.


Subject(s)
Antigens/pharmacology , Gene Expression Profiling , Receptors, Antigen, T-Cell, gamma-delta/immunology , Receptors, Antigen, T-Cell/immunology , Receptors, Notch/immunology , T-Lymphocyte Subsets/drug effects , Transcriptome/immunology , Antigens/chemistry , Humans , Interleukin-2/pharmacology , Lymphocyte Activation/drug effects , Lymphocyte Activation/genetics , Receptors, Antigen, T-Cell/genetics , Receptors, Notch/genetics , Signal Transduction/drug effects , Signal Transduction/genetics , Signal Transduction/immunology , T-Lymphocyte Subsets/immunology , Transcriptome/genetics
2.
Biotechnol Lett ; 37(1): 227-33, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25257585

ABSTRACT

To explore a novel source for the derivation of islets, we examined the differentiation potential of human non-pancreatic cancer cell lines, HeLa (cervical carcinoma cell line) and MCF-7 (breast cancer cell line). These cells were subjected to a serum-free, three-step sequential differentiation protocol which gave two distinct cell populations: single cells and cellular aggregates. Subsequent analysis confirmed their identity as pancreatic acinar cells and islet-like cell aggregates (ICAs), as evidenced by amylase secretion and diphenylthiocarbazone staining respectively. Reverse transcriptase-PCR and immunocytochemistry assessment of the ICAs revealed the expression of pancreatic specific markers Ngn-3, Glut-2, Pax-6 and Isl-1. These ICAs secreted insulin in response to glucose challenge, confirming their functionality. We propose that ICAs generated from HeLa and MCF-7 cell lines could form a promising in vitro platform of human islet equivalents (hIEQs) for diabetes research.


Subject(s)
Cell Differentiation/physiology , Islets of Langerhans/cytology , Islets of Langerhans/metabolism , Spheroids, Cellular/cytology , Spheroids, Cellular/metabolism , Amylases/metabolism , Cell Line, Tumor , Culture Media , Glucose/pharmacology , HeLa Cells , Humans , Islets of Langerhans/drug effects , Spheroids, Cellular/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...